Astera Cancer Care, an independent, physician-owned multi-specialty oncology practice, has yet again achieved another significant milestone by enrolling the world’s first patient in phase 3 of the IDeate-Lung02 clinical trial. This groundbreaking study aims to compare the efficacy and safety of Infinatamab Deruxtecan (I-DXd) with physician’s choice of chemotherapy standard treatments chosen by physicians for patients with relapsed small cell lung cancer (SCLC). Conducted across 229 global sites, this trial highlights Astera’s commitment to advancing cancer treatment and research, marking a historic moment as they lead the way in this critical clinical study.
IDeate-Lung02 is enrolling patients with relapsed small cell lung cancer (SCLC) who are 18 or older, have received a prior platinum-based treatment, and must have measurable cancer that has progressed.
The trial utilizes two primary measures to assess the effectiveness of the treatments: Objective Response Rate (ORR) and Overall Survival Rate (OS). ORR evaluates how well the cancer responds to the treatment by examining the percentage of patients whose tumors shrink or disappear after receiving therapy. OS measures the length of time in which patients live from the start of treatment.
The trial also explores various secondary objectives to better understand the efficacy and safety effects of Infinatamab Deruxtecan (I-DXd). These include evaluating how patients feel and function while on the drug in order to determine if the drug triggers an immune response by being recognized by the body as a foreign object, as well as monitoring any changes in the levels of B7-H3, a protein believed to have potential involvement in cancer progression. Additionally, the study strives to characterize the pharmacokinetics of I-DXd, involving the understanding of how the drug is processed and absorbed by the body.
Astera Cancer Care is dedicated to providing patients with cutting-edge treatments and advancing the field of cancer research. Those interested in participating in these clinical trials can find the eligibility criteria on clinicaltrials.gov (NCT06203210).
To make an appointment at Astera Cancer Care, please call (732) 390-7750.